Transforming Bone Disease Diagnosis with Dominik Maurer from Bonescreen

Episode Overview

Episode Topic: 

In this episode of “The Skeleton Crew,” host Jen Callahan welcomes Dominik Maurer, CFO and co-founder of BoneScreen, a company based in Munich specializing in the detection of osteoporosis through advanced radiology tests. The discussion centers around the innovative products developed by BoneScreen that are revolutionizing the early detection and prevention of osteoporosis, a condition that often goes undiagnosed until it causes significant harm. Dominik shares insights into how their technology integrates with existing CT scans to identify bone mineral density issues without the need for additional scans. This episode provides a deep dive into the importance of early detection and the technological advancements making it possible.

Lessons You’ll Learn:

Listeners will learn about the significance of early osteoporosis detection and how BoneScreen’s technology can play a crucial role in preventing severe bone health issues. Dominik explains the process of integrating BoneScreen’s products with routine clinical CT scans, emphasizing the importance of opportunistic screening. The episode highlights the shift towards preventative healthcare and the role of AI in assisting radiologists by reducing their workload and enhancing diagnostic accuracy. Additionally, listeners will gain insights into the challenges and opportunities in implementing new medical technologies within diverse healthcare systems.

About Our Guest:

Dominik Maurer is the CFO and co-founder of BoneScreen, bringing a unique perspective to the intersection of finance and radiology. With a background in finance, Dominik joined forces with Janine and Johnny, who had the initial idea of turning BoneScreen into a commercial product. His journey from finance to the medical technology sector has been driven by a passion for making a positive impact on patient health. Since dedicating himself full-time to BoneScreen, Dominik has been instrumental in securing funding and navigating the regulatory landscape to bring their innovative products to market.

Topics Covered: 

The episode covers a range of topics, starting with Dominik’s background and his transition from finance to co-founding BoneScreen. The conversation delves into the technical aspects of BoneScreen’s products, SpineQ and SpineRQ, explaining how they help detect osteoporosis using CT scans. Dominik discusses the prevalence of osteoporosis, the importance of early detection, and how BoneScreen aims to address these challenges. The discussion also touches on the regulatory hurdles faced in different markets, the potential expansion of BoneScreen’s technology to other types of scans and geographies, and the overarching goal of shifting healthcare towards a more preventative approach.

Our Guest: Dominik Maurer, Visionary CFO and Co-founder of BoneScreen, Revolutionizing Osteoporosis Detection

Episode Transcript

Jen Callahan: Hey, everybody, welcome back to another episode of The Skeleton Crew. I’m your host, Jen Callahan, and today I have a great guest with me. He’s joining me from Munich. His name is Dominik Maurer, and he’s joining me from a company called BoneScreen. They’re talking about all things bone-related and what they’re using to help detect Osteoporosis in different radiology tests that are being performed.  Dominic, thanks for being with me today.

Dominik Maurer: Pleasure to be here, Jen.

Jen Callahan: Thanks. I’m going to leave you to talk about the technicalities of the company.  and kind of where you guys are currently at and then where you’re going. But for us, let’s start with you, and maybe can you give me a little bit of a background of yourself and how you found yourself being a CFO and a co-founder of this company.

Dominik Maurer: Yes. No. Happy to and thanks again for, for having, for having me here.  yeah. I think it doesn’t always happen that there’s a guy from finance who ends up in radiology. So I think my path was a little bit, I would say rather unexpected when I,  now two and a half years ago, met two of my co-founders, Janine and Johnny, who kind of had the initial idea or the on-screen turning the bone screen into a commercial product.  but realized that they also needed somebody to cover the business side. I was pretty fond of their idea right away, and I thought this could have a really big impact and really affect,  positively affect a lot of patients moving forward. So started to do this kind of working a little bit with them on the side, trying to find some financing funding for, for our for, for the idea. And  then once we got it, I’ve now been with  bone screen full time since,  since one,  exactly one year basically to date.  and,  it’s been a quite a journey so far, I can tell you.

Jen Callahan: Yeah. I’m sure,  leaving the financial world and then finding yourself in, in a radiology company.  but interesting for sure.  So let’s move on to the bone screen.  so products that have been developed to help with detection of osteoporosis.  I feel like osteoporosis probably isn’t talked enough about in the world in general.  and it’s one of those things that probably to someone who’s not working with bones, bone scans,  like Dexa and things like that, it’s not really something that’s on your mind or on the forefront.  but so let’s talk about the two different products that bone screen has.

Dominik Maurer: And we are happy to, I think, and maybe let me just quickly pause here and also say, I think you hit the nail on it. Right? Because the whole idea also came from the fact that osteoporosis is unfortunately very un under-diagnosed and really remains a silent killer if you want to put it like this, or a silent cause of osteoporotic fractures. And unfortunately with bone health, I think it’s a topic that people tend to neglect until it’s too late and until the fracture occurs. And this is also why we came up with our two products. Right now we have spine cues and we have spine cues for quantification because we’re quantifying the spine and we are extracting the bone mineral density based on spinal CT scans.  and spine are because that is kind of our research version which we are selling  to. Basically everybody is doing research on the spine. We have customers using it in Canada, in the US, actually in Philadelphia or I know, I think in North Carolina and all across Europe.   I would have to say though, that spine cue is currently in the process of CE certification for the background for your American listeners. That’s the FDA equivalent, right? So we’re currently in the process of getting that approval, which is why at this point, we cannot,  commercially, sell the services of Spine Cue yet.

Jen Callahan: Okay.we’re saying, you know, like going undetected, I feel like so I have dabbled in Dexa myself, you know, performing Dexa scans,  at different locations that I’ve worked at. And generally the people that are coming in for scans and getting bone scans,  are usually women who are postmenopausal. then sometimes you might see males come through depending on if they have, you know, maybe if they’ve been treated for cancer and, you know, have gone through chemotherapy. like you said, it’s pretty much you’re coming, you’re getting tested and detected.  Well, after the fact of probably when you really should be,  you know, maybe it really should be something that should be looked at for adults, you know, maybe like 40 and up or even in their 30s, you know what I mean? Like, it’s never too late to or never too early, I should say to care for your body. Right.

Dominik Maurer: No, I couldn’t agree more. Exactly. And I think, I mean, you’re preaching to the choir here, right?  I myself, in the age of,  30, mid 30s and  I think from and this I think is also the kind of the idea behind bone screen that we take any routine clinical CT scan and we opportunistically scan it on top of the original diagnosis. It could be completely unrelated to an osteoporotic fracture, but abdominal pain for example. And on top of that we screen the CT scan. We extract the BMD  and then play it kind of in the form of a report into the PACs. So the physician or the radiologist could use that and for an additional diagnosis on top. And we do classify between whether you’re osteopenia or whether you’re kind of highly osteoporotic. And depending on in which area you land, you already have a good indication of whether you should start taking preventive kind of action through be that supplements vitamin D,  and kind of like doing more sports, things like this because unfortunately,  I think we do,  live in times where we live a little bit unhealthier lifestyles. We do have demographic change.  so people are getting much older. And I think this is also I’m sure we’re going to touch up on this later. Right. The idea behind bone screen taking,  I would say a preventive approach rather than unfortunately, our healthcare system being very reactive.  at least in Germany, it is the case we’re seeing some trends in the Scandinavian countries who seem to be at the forefront of more prevention, I don’t think I’m not sure what’s your perception about the US, but I still think we live more in reacting rather than being proactive and taking kind of life or like health into our own hands.

Jen Callahan: I definitely feel in the US, and especially since I’ve been having,  since I’ve started with the podcast and speaking to many different people within healthcare. That the US is trending towards trying to do preventative medicine.  in terms of things related to cancer.  probably just because cancer is so prevalent, I think it’s so prevalent at this point because,  The screenings are better. You know, maybe you’re possibly getting more Cat scans of something or x rays or, you know, I think that the technology there is just,  more advanced than what it was in the past.  but again, so you’re looking really more at like preventative measures towards cancer, but, you know, bone health is very important, you know, because it leads you down the path of like, what if you just fell down the steps, you know, maybe two steps and you broke your hip and you’re like, why do I break my hip? Well, the person could have been osteoporotic, like you said,  and didn’t even know it because those preventative tests weren’t done in place. And, you know, they didn’t know to be taking their vitamin D or, you know, how important,  like weightlifting, not weightlifting. It sounds kind of weird, but you know what I mean?  to get bone strength. How important stuff like that is.

Dominik Maurer: Yep. Yep. I couldn’t agree more. Yeah.

Jen Callahan:  So you guys have these two, and you said that you’re in the process of getting the clearance for the queue.  Are you guys trending in, in any other direction to move the company into,  maybe other areas for bone health? Because indexes scan the two areas that we normally scan.  are the hips.  and then the lower back. So I’m not sure. Like, would it possibly be used in Cat scans of the hips or, you know, pelvis region?

Dominik Maurer: Yes. And I think,  like, this is a really good,  really good question. And I think it’s a little bit in terms of the overarching,  the overarching strategy that we have for our company. Right. And I think I heard and we live by the principle, go big or go home.  I think if we didn’t believe in our technology and if we didn’t want to kind of spread this and scale it towards others,  I would say and we always talk in three dimensions. One is the modalities. So like you said, different MRIs,  CT scans.  Then we think big in terms of extremities. So right now we’re limited to the spine by nature. We want to make sure that we cover a wider array of all CT scans,  and of including the arms, the legs,  larger points, like, for example, the hip,  potentially the knee makes sense, right. So that there would be some extremities. And then in the last step in terms of,  kind of like besides modalities and extremities, we also do look at different geographies. Right? We want to make sure that we, we also can,  reach as many patients as possible. So for us the next step after see is definitely looking at FDA approval. Since the US is a very big,  big healthcare market. So I think this is a little bit,  the, the vision that we have for bone screen and where we want to see ourselves in 5 to 10 years really covering, I would say, not only just limiting ourselves to spinal CTS because I think,  we want to cover, like, serve as many patients as possible. And you can’t do that if you limit yourself to, to to only to only the spine.

Jen Callahan: The technology itself or the product,  you said that, you know, it coincides with the Cat scan.  Is that something that when it’s integrated into, say like a PACs program or something, is it something that the radiologist would have to choose for it to be used, or is it something that would just automatically be done? Because from different discussions that I’ve had with companies who are doing AI related work, you know, sometimes it’s something that they choose to, to run on, like the image or the report that they’re doing. This episode is brought to you by xraytech.org, the Rad Tech Career Resource. If you’re considering a career in radiology, check out X-rayTech.Org to get honest information on schools, degree options, career paths and salaries.

Dominik Maurer: I think this is a really good question as well because it really depends on preferences. And I think for us, we are we, we are looking to provide solutions to, to cater kind of for all sorts of client requests. Some like to take matters in their own hands and kind of would prefer to choose the patients. And I think this also makes more sense given,  you also want to make sure that you’re not automatically running on adolescence scans, which we basically want to exclude. Right.  and if you, if you really do see, okay, this is a 20, 22 year old, I don’t know who’s done sport all, all their lives so far. The question would be, do you want to include that person? Our vision would or our preference would always be to run it via as many scans as possible, because I think we always say, and I think this is the philosophy of a lot of startups in that space, that we want to detect things where the radiologist would not see things. Right.  so we want to come in and really be that second opinion that,  AI driven co assistant to the radiologist to give us that second opinion and to potentially find things that would otherwise be missed.

Dominik Maurer: The idea would definitely be  like preference would be for, for us to run in over each scan automatically. But I think this is really difficult even in some countries due to regulatory problems.  but right now the idea would be that you proactively choose which patient you want to kind of scan on top of the Cat scan that the person is receiving.  anyway. And then it also depends. I’m sure you’ve covered this,  in some of your episodes, the rise of the AI marketplace.  so it also depends if you’re kind of an app as part of a of of, of an AR marketplace and the kind of the radiologist needs to deliberately choose you or whether you are kind of directly installed within the, within the infrastructure of the of of the hospital bid on the, on the hardware kind of on an extra hardware depending on data protection.  I’m sure we’ll talk about that later on a little bit as well.  yeah. Due to data protection problems in Europe, I think it really depends. So unfortunately, it’s not that clear cut of an answer that I would like to give.

Jen Callahan: For when you’re integrating it does bone screen do they know suggest criteria for what. For the patients that shouldn’t have this run on, you know, like how we were discussing, like, you know, if you’re a 22 year old, you know, adolescent, you’re probably not going to run it. But, you know, maybe looking at different demographics like,  I don’t know if there’s certain ethnicities that are prone to osteoporosis.  I don’t know that off the top of my head, but thinking maybe, you know, women like 40 and up,  of this ethnicity, you know, running on that or,  or like males, like 60 up. Dude, do you guys suggest criteria like that?

Dominik Maurer: Interestingly, we will not try to limit ourselves by nature. So I think that the key limitation is that we would like to avoid the other, other scans in adolescence. And we do obviously, I think we have a couple of requirements on the technical side, for example, that you need to have, I don’t know, x,  gigabytes of Ram, minimum requirements from, from your technical IT infrastructure. But then I would say on the intended purpose, how we call it here we are.  kind of like, as I would say, the patient group, we’re not limiting ourselves. So anybody beyond 18 could potentially receive a scan. By nature we would or we would always encourage that. If you’re above a certain risk age, you should definitely always scan your patients. For example, women aged 40, 50 years and above are menopausal. Women, I think, are cross. I just read a couple of weeks ago, I read a study that was done, I think it was in Korea or Japan, and they had similar levels of fracture risk,  as compared to European women. So I think this tends to be, like you said, I think there is no clear ethnicity that or gender group that is more prone. But we do see it when we look at more elderly people. So I think the more the older the patient is, the more  the more relevant such a scan gets for them. However, I also want to make sure that if a patient is 40 years old and already osteopenia has osteopenia. I also would like to detect that because this is actually where I can prevent it. Right, right. I still would encourage everybody to at least  kind of take,  take the patient’s parameters into consideration. But in the end, I still think,  we don’t want to limit ourselves too much either.

Jen Callahan:  So you guys use this with Cat scans? Are you looking to,  implement it into other types of,  scans, like MRI or,

Dominik Maurer: Yes.

Jen Callahan: So even general X-ray, possibly like a, you know, a play, I think,

Dominik Maurer: We’ve already seen a couple of,  we’ve already seen a couple of people making an attempt to do it in x-ray. We,  and ultrasound as well, actually,  interestingly, we do or as part of and I have to refer to my colleagues here because I think they’re the expert. Right. I think I should have stated this at the beginning as well. So our team is a very strong co-founding team. We have three,  developers, and we have two,  professors and doctors from  with a background in radiology as well. I think we do have the users,  as well. And like, I think one of my co-founders, the one I like, I mentioned at the beginning where it all started with Yan, he has done, I think his journey with osteoporosis started 20 years ago when he did his doctoral dissertation on that matter. So we have a lot of data. We have done a lot of research, and research just points to CT scan being the best modality for conducting BMD scans. And then now in the next step, we are,  one of my other colleagues. He just looked at MRI scans and annotated those over the last couple of days, or I think almost weeks now.  since we want to move into MRI as well, and we’re currently exploring options to do that, since we do see a lot of value and potential angle here as well.

Jen Callahan: I mean, it makes sense that Cat scan and MRI would probably be the two main,  because it’s cross-sectional anatomy. So it’s looking at the bones and in multiple different aspects. So that definitely makes sense.  I mean, plain X-ray is great for many different reasons.  and that’s usually insurance wise, I don’t know how it is in Europe, but insurance wise in the United States, you pretty much always have to start with an x-ray first before they’ll allow you to move on. Generally, I feel like depending on what the diagnosis is or what the reason is for,  the study that’s being performed. But generally you’re always starting with an x-ray.  but it definitely makes sense. Like I said, because of the cross-sectional anatomy,  standpoint for MRI and CT.  So is this currently implemented in, you know, different healthcare systems in Europe?

Dominik Maurer: Yes. So as I said before, our research version is being used across the world almost, I would say. So we have users using our spinal segmentation, our, I would say, soon to be certified products bank is already being tested as an MVP basis, not for clinical purposes. I should add as a small disclaimer in different university hospitals in Germany, in Switzerland, and I think with a really good feedback so far.  which obviously makes us happy. So we’re also currently in contact with different doctors in the UK, in Sweden, because we want to make sure that we kind of start engaging early with them,  in order to highlight. And I think the feedback that we’ve received so far has been very reassuring.

Jen Callahan: That’s great, that’s great. I was going to ask about the feedback,  does this ever come across the hands of, like any of the technologists that are like performing the scans or is I mean, it’s really on the back end, I guess.

Dominik Maurer: You mean in terms of,   in terms of,  the technology or in terms of.

Jen Callahan: Like the Cat scan technologist who would be with the patient,  placing the patient on the table, performing the scan.  just wondering if maybe, maybe do they have to do anything different to help with the scan or do they have anything to do with it? Or it’s really just radiology from the radiologist standpoint, like the doctor themselves who are doing the readings.

Dominik Maurer: Yeah. Okay. No, I get it. Yes.  so I think there would not be a lot of touch points. It depends on how I would say how the clinic is structured. So in Germany, how it works is that you would come into the clinic as a patient and then it would mainly be the kind of the people at the reception who would educate you about the possibility of getting another scan on top of your Cat scan that you are due to, to take. The technical people would not so much be involved in anything other than potentially setting up the infrastructure, but I think then the decision making process would lie with the radiologist ultimately.  Also I think the key benefit for, for, for the tech,  technical team,  would lie in that they would hopefully have more time since they don’t have to conduct textiles anymore.

Jen Callahan: Okay.

Dominik Maurer: Gotcha. Perfect.

Jen Callahan: So it sounds like you guys have developed a great product here.  definitely useful. You know, where patients aren’t having to get additional scans on top of something that can just be integrated with a scan that’s already being done, like you said. Like, what if they’re going to the ER for abdominal pain and the doctor there orders, you know, an abdomen CT, then they can just look at the spine and you know from there, you know, if they do need something additional, but you know, it’s being detected, which is awesome.  have you guys, since the company has developed in the two different products that you have, the spine or, and the spine. Q have you faced any challenges like clearances or integrating it into different health systems?

Dominik Maurer: Yeah. Yeah. I think it’s a very good question. And I would be lying if,  if I said we hadn’t faced any challenges. Right. I think this is especially in the healthcare market. Right.  and  and I think maybe just one comment to, to to what you said now,  just now I think is for us, we always try to,  it sometimes we feel a little bit like you’re recycling the, the CT scan, or at least you’re trying to, like, kind of tap into this big ocean and try to lift the data treasure that is hidden in all of these scans, which we’re just using to a very tiny bit right now. And by doing that, obviously you do encounter a lot of challenges, especially looking at governance structures across Europe, because I don’t have to tell you how,  after you’ve also talked to a couple of European companies already. Right. Unfortunately, the healthcare market is very, very fragmented, and that doesn’t make it really easy for smaller startups and for smaller companies to find those markets that,  kind of seem to be appreciating or fitting for them,  kind of in or in need of their product. So I think for us, it’s really,  since we are German based, obviously this is by nature we understand the German market. We will kind of have that as our market moves forward. But we are already looking beyond and I think there is a little bit of a complexity sometimes, which doesn’t make it easy given,  you have an insurance based healthcare system, you do have national healthcare systems.

Dominik Maurer:   The fragmentation is very challenging I would say. .  the second challenge is definitely finding the right personnel. I think this is a question that all companies have, and especially if you’re looking for,  software people that work within AI and are also kind of knowledgeable on the medical kind of side, I think this is something that is very,  like kind of Arthur’s sort sought after and that is not so easy to,  kind of,  to, to attract those talent. And I think this is definitely would say, two major challenges that the, the last one being that you need,  like, unfortunately, you also can’t just once you have the CE mark in Germany,  or for Europe,  you would still need the FDA approval, which is a timely process to get into the US despite there not being a lot of differences. Right? I think,  obviously the markets function differently, but I think we are still kind of almost on equal standards.  to, to some extent,  where I would hope or I would wish that there is a little bit of less regulatory burden.  you need different,  yeah, different marks for different countries, Japan, etc..I think it’s definitely challenging.

Jen Callahan: Yeah, definitely.

Dominik Maurer: Exciting to write.

Jen Callahan: Challenging and exciting. I mean, if it were, if it wasn’t challenging, I mean, everyone would be doing it. Not I mean, not not phone screen, but, you know, I mean, there has to be challenges. I was just having this conversation with my son today. I said, if you expect someone to just do everything for you, I don’t know how your life is going to end up.  but I mean, definitely useful,  with like a lot of AI stuff that is developed out there, that it’s there to help the radiologists and the technologists and to help with preventative care, you know, helping the radiologists to do almost less readings. You know, it’s one less possible Dexa scan that the patient might have to do. So it’s one less reading that the radiologist would have to do. You know, the conversation right now is so much about radiologist burnout, even technologist burnout,  because of the influx of scans that are being done, and therefore so many reports that have to be done as well. So it’s great that it’s there as a tool to aid the radiologist,  in detecting, you know, osteoporosis and looking at bone health.

Dominik Maurer: Yep. Yes. And I think to add to that right. We always want to. In the forefront should always be the user and the patient. So ultimately what we want to do, we want to make radiologists life easier and add value to the patient at the same time. And I think with a bone screen, we found a very nice and niche way of doing that, because on the one hand, we do free up radiologist time. Our scans can be like if we run in the background, I think it takes us less than a minute for our scan to run in the background, so there is not much additional time. We know how much radiologists value their time and how they don’t want to indulge in excessive additional work. Right. I think we really try to kind of solve for that by basically making this additional Dexa scan obsolete. We’re saving time. There we are.  still kind of trying to save,  yeah. Like we touched up on before,  nurses or technical technical personnel that are dealing with the scans, their time is freed up and we’re trying to maximize patient value because they get access to quicker, like, earlier diagnosis. I think we, we really nicely fit into,  into a niche of, of only a few products that actually,  helps doing that.

Dominik Maurer: And I really hope we can continue kind of our journey and, and also make ourselves even more attractive by adding more modalities moving forward. Because what I fear a little bit at this point is that we have so many startups coming out. And,  if, if, if you were to choose, I think you could run 4D scans from, from 30 different startups soon.  over one,  one scan. Right. And this is something that I think we have to make sure we don’t overburden, like you said, with regards to not cause burnouts across the few radiologists that we already have, because the numbers are not growing, unfortunately, rather stagnating. And the people that need scans are increasing. Right. So we really need AI to make your guys’ lives easier and not even put you into the shoes of having to choose between 50 different solutions. Now, but you just want to go there, use the smoothest one. And we kind of really have the vision to become one of those tools that does that.

Jen Callahan: What sounds like you guys were going in the right direction for sure.  and I mean, at this point with different companies that I’ve spoken to in the past year or so since the podcast has been going on, this is the first that I’ve spoken to anyone about looking at preventative bone health.  I mean, I really love it.  just overall because my eyes were open to bone health. Like I said, when I started doing Dexa scans and this kind of just I started at a place where,  if you worked in x-ray, you also had to cover Dexa. So I did on the job training. And, you know, you learn a lot while you’re doing it and the different questions that you need to ask and the different patients, you know, with,  you know, not disease. I don’t want to say diseases, but,  you know, people who are going through cancer treatment, you know, how much chemo affects, you know, bone health and even,  say, patients, men or women who have, like, eating disorders, you know, how much that can affect your bone health? So it’s eye opening. And I really loved, you know, the trend that you guys are going in. So I really appreciate your time to talk with me today.  no. Go ahead.

Dominik Maurer: Yeah. No.Yes.  Thanks a lot. And I think one last point that I maybe also want to stress is,  to, to really give patients end users, I think also the reassurance. Right. And I think this will be a very important thing for everybody, maybe listening to this podcast keynote, starting their own radiology startup at some point in the future. I think what really is important, and we’ve come to realize this now by talking to clinics, to radiologists, that you already bring in the evidence. So this might sound encouraging, right? But because one of my whole founding co-founding team, we’ve published numerous clinical validations, cost efficiency studies. So we have all of the evidence backing up our claims. And I think this is one thing that whoever’s listening and who feels like, okay, I’ve done a lot of research. I actually found something there. This should give you a lot of comfort to actually go out and maybe even try something like this.  yourself or push out the ideas, because there are people out there that are looking for exactly that, the evidence based healthcare. And I think this really also is one of the points that distinguishes us from, from a lot of other startups. And if there’s people out there who also have that, I think I will always salute you because I think it is really important that we not lose the evidence behind or behind the claims. Yeah.

Jen Callahan: I’m happy that you brought that up.  because that’s something I meant to touch on that you guys have a slew of peer reviewed journals,  or articles and that’s that’s amazing. You know, that you’re doing your own, obviously, your own research behind the stuff that you’re,  that you’re developing. But how much peer review articles that you have is impressive.

Dominik Maurer: Yeah.

Dominik Maurer: No, thanks. Yes. We’re very proud of that.

Jen Callahan: All right, well, everybody, this is Dominik with me,  talking about bonescreen,  for bone health and listening to our conversation. If you’re not out there, you know, caring for your body and, you know, taking care of your bones, you should be. It’s never too late. It’s never too early to start, right? Yeah.

Dominik Maurer: Exactly.

Jen Callahan: Yeah. All right, everybody, we’ll see you next week. Thanks for being with us.Jen Callahan: You’ve been watching the Skeleton Crew, brought to you by X-rayTech.Org. In the next episode, join us to explore the present and the future of the Rad Tech career and the field of radiology.